Keros Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $87.0M | $-187.4M | $-153.0M | $-104.7M | $-58.7M | $-45.4M | $-12.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $1.5M | $1.2M | $815.0K | $674.0K | $378.0K | $278.0K | $208.0K |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $28.7M | $34.9M | $28.8M | $18.7M | $11.7M | $4.1M | $59.0K |
| Net Cash from Operating Activities | $107.5M | $-160.9M | $-124.5M | $-70.1M | $-62.1M | $-36.9M | $-16.0M |
| Investing Activities | |||||||
| Capital Expenditures | $1.6M | $1.9M | $2.5M | $1.2M | $1.0M | $294.0K | $271.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.6M | $-1.9M | $-2.5M | $-1.2M | $-1.0M | $-294.0K | $-271.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | $375.0M | $0 | — | — | — | — | — |
| Net Cash from Financing Activities | $-378.5M | $391.8M | $179.0M | $120.3M | $28.6M | $296.0M | $14.0K |
| Net Change in Cash | $-272.5M | $229.0M | $52.0M | $49.0M | $-34.6M | $258.9M | $-16.3M |
| Free Cash Flow | $106.0M | $-162.8M | $-127.0M | $-71.3M | $-63.2M | $-37.2M | $-16.3M |